{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-22-000011","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.052490+00:00","generated_at":"2026-06-26T00:12:03.668045+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vertex Q1 product revenue $2.10B (+22% YoY); reiterates FY 2022 guidance $8.4-8.6B","bullets":["Product revenues $2.10B (+22% YoY); TRIKAFTA $1.76B (+48% YoY).","GAAP diluted EPS $2.96; Non-GAAP diluted EPS $3.52 (up 18% YoY).","Reaffirmed FY 2022 product revenue guidance $8.4-8.6B.","Pipeline spans 6 disease areas; positive Phase 2 proof-of-concept studies; more therapies entering clinic H2 2022.","Changed non-GAAP methodology; no longer exclude certain R&D milestone payments; recast prior periods."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-22-000011","json":"https://secwatch.observer/filing/0000875320-22-000011.json","markdown":"https://secwatch.observer/filing/0000875320-22-000011.md","text":"https://secwatch.observer/filing/0000875320-22-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000011/0000875320-22-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000011/vrtx-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:12:03.668045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}